# Cellus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellus

- Industry: Healthcare
- Headquarters: Daegu, South Korea
- Website: www.cellusbio.com
- Total disclosed funding: $1M
- Latest round: Seed (Jun 1, 2020)
- Investors on record: 3

## About

Based in Daegu, South Korea, and founded in 2020, Cellus is an innovative company that conducts cell experiments with new antibody drugs produced within a year of its establishment. Founded by Dr. Seong-geun Kim from the Department of Pathology in Gatrick Medical University and Professor Chosun-wook Cho of the Department of Endocrinology in Seoul National University Hospital to jointly develop a next-generation anticancer drug, the anti-cancer treatment strategy developed by the company has a modified function called Tumor-Associated Macrophage or TAM that deactivates cancer growth and metastasis rather than its original function. Based on this, an antibody therapeutics and low-molecular compound therapeutics that block the mechanism by which tumor-associated macrophages promote cancer cell metabolism has been developed.

The company develops and manufactures anticancer drugs that overcome the shortcomings of low therapeutic effects of third-generation immunotherapy, which are currently the mainstay of anticancer drugs, use the relationship between immune cells and cancer cells in the cancer microenvironment to control factors that promote cancer growth and metastasis.

Cellus plans to complete the initial production of four new drug substances under development within this year and conduct cell and mouse basic experiments in Korea.

## Funding rounds

- Seed, Jun 1, 2020, $1M — Bluepoint Partners, Hyundai Investment Partners, Enlight Ventures

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed
- Hyundai Investment Partners (https://capitalatlas.ai/funds/hyundai-investment-partners) — Seed
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Seed